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ABSTRACT
Dysregulation of cellular transcription and translation is a fundamental hallmark 
of cancer. As CDK9 and Mnks play pivotal roles in the regulation of RNA transcription 
and protein synthesis, respectively, they are important targets for drug development. 
We herein report the cellular mechanism of a novel CDK9 inhibitor CDKI-73 in an 
ovarian cancer cell line (A2780). We also used shRNA-mediated CDK9 knockdown 
to investigate the importance of CDK9 in the maintenance of A2780 cells. This study 
revealed that CDKI-73 rapidly inhibited cellular CDK9 kinase activity and down-
regulated the RNAPII phosphorylation. This subsequently caused a decrease in the 
eIF4E phosphorylation by blocking Mnk1 kinase activity. Consistently, CDK9 shRNA 
was also found to down-regulate the Mnk1 expression. Both CDKI-73 and CDK9 shRNA 
decreased anti-apoptotic proteins Mcl-1 and Bcl-2 and induced apoptosis. The study 
confirmed that CDK9 is required for cell survival and that ovarian cancer may be 
susceptible to CDK9 inhibition strategy. The data also implied a role of CDK9 in eIF4E-
mediated translational control, suggesting that CDK9 may have important implication 
in the Mnk-eIF4E axis, the key determinants of PI3K/Akt/mTOR- and Ras/Raf/MAPK-
mediated tumorigenic activity. As such, CDK9 inhibitor drug candidate CDKI-73 should 
have a major impact on these pathways in human cancers. 
INTRODUCTION
Cyclin dependent kinases (CDKs) are a family 
of serine/threonine kinases, whose activity is tightly 
associated with specific cyclin co-factors. Over the last 
decade, more than 20 CDKs have been characterized and 
are generally classified into two major groups, based on 
whether their primary role is involved in the control of 
cell cycle progression or the regulation of transcription. 
Multiple CDKs control the cell cycle and are essential 
for normal proliferation, development and homeostasis. 
CDK4/cyclin D, CDK6/cyclin D and CDK2/cyclin 
E facilitate the G1-S phase transition by sequentially 
phosphorylating the retinoblastoma protein (pRb), while 
CDK1/cyclin A, CDK2/cyclin A and CDK1/cyclin B are 
essential for S-phase progression and G2-M transition, 
respectively [1].
Inhibition of transcriptional CDKs as an effective 
anti-cancer strategy has gained considerable attention 
following the observation that many types of cancer cells 
Oncotarget7692www.impactjournals.com/oncotarget
rely on the production of short-lived mitotic regulatory 
kinases and apoptosis regulators such as Mcl-1 for 
their survival [2, 3]. CDK7/cyclin H is a component of 
transcription factor IIH (TFIIH) that phosphorylates 
the serine-5 residues within the heptad repeats of RNA 
polymerase II (RNAPII) C-terminal domain (CTD) to 
initiate transcription [4, 5]. CDK9/cyclin T, the catalytic 
subunit of positive transcription elongation factor P-TEFb 
[6, 7], phosphorylates two elongation repressors, i.e. the 
DRB-sensitive-inducing factor (DSIF) and the negative 
elongation factor (NELF), and serine-2 of the CTD heptad 
repeats to facilitate a productive transcription elongation 
[3, 8]. Apart from having a role in RNA transcription, 
CDK7 is also a CDK-activating kinase (CAK), which 
phosphorylates and activates multiple cell cycle CDKs [5]. 
In contrast, CDK9 appears to have a minimal effect on cell 
cycle regulation [9]. 
Over the last decade, an intensive search for 
pharmacological CDK inhibitors has led to the 
development of several clinical candidates and to the 
realization that inhibition of the transcriptional CDKs 
underlies their anti-tumor activity [3, 10]. Flavopiridol 
(alvocidib), the first CDK inhibitor to enter clinical trials, 
is the most potent CDK9 inhibitor identified to date and 
has demonstrated marked anti-tumor activity in chronic 
lymphocytic leukemia (CLL) [11, 12]. Flavopiridol has 
been shown to inhibit multiple CDKs [13] and other 
kinases [14], but the primary mechanism responsible for 
its observed anti-tumor activity in CLL appeared to be the 
CDK9-mediated down-regulation of transcription of anti-
apoptotic proteins [15]. 
R-Roscovitine (seliciclib) is the first orally 
bioavailable CDK inhibitor that targets CDK2, CDK7 
and CDK9 (IC
50
 = 0.1, 0.5 and 0.8 µM, respectively) 
[16-18]. Initial evaluation in clinical trials indicated its 
well tolerance and some evidence of disease stabilization 
was reported [10]. Phase-II clinical trials are currently 
underway in patients with non-small-cell lung carcinoma. 
R-Roscovitine has demonstrated selective induction of 
apoptosis in cancer cells by down-regulation of anti-
apoptotic proteins through transcriptional CDK inhibition 
[19, 20]. Other CDK inhibitors, including AZD5438 [21], 
R547 [22, 23] and AT519 [24], have also been evaluating 
in clinical trials.
Recently, the first-in-class CDK4/6 inhibitor PD 
0332991 [25, 26] (palbociclib) has demonstrated marked 
anti-tumor activity in post-menopausal women with 
estrogen-receptor positive and HER2-negative advanced 
breast cancer. However, non-luminal/basal subtypes were 
resistant to PD 0332991. Cell cycle analysis showed G0/
G1 arrest in sensitive cell lines and Western blot analysis 
demonstrated that retinoblastoma phosphorylation 
(pRb) is blocked in sensitive, but not resistant lines. 
Hyperphosphorylation of Rb is mediated by CDK4 and 
CDK6 in early G1 phase through the interaction with 
cyclin D. This results in Rb inactivation and release of 
transcription factors that allows cells progress toward 
S phase. PD 0332991 showed significant hematologic 
toxicity and dose reduction for hematologic toxicity was 
required for 24% of patients in clinical trials [27]. 
Mitogen-activated protein kinase (MAPK)-
interacting kinases (Mnks) are also members of the 
serine/threonine kinase family, and are emerging anti-
cancer targets [28]. As one of the key effectors for the 
MAPK pathways, Mnks are activated by the extracellular 
signal-related kinase (Erk) and p38 kinase in response to 
extracellular stimuli. Subsequently, Mnks phosphorylate 
residue  serine-209 of the eukaryotic initiation factor 4E 
(eIF4E), a key component of translational control [29]. 
Recent findings suggested that eIF4E is a key determinant 
of PI3K/Akt/mTOR- and Ras/Raf/MAPK-mediated 
tumorigenic activity, and that targeting eIF4E should 
have a major impact on these pathways in human cancers 
[29]. Phosphorylation of eIF4E by Mnks at serine-209 is 
considered to be critical for the oncogenic role of eIF4E. 
It has demonstrated that mice carrying a serine-209Ala 
eIF4E mutant were incapable of developing cancer. 
While Mnk1/2-double knock-out tPTEN-/- mice showed 
diminished tumour growth compared to the parental 
tPTEN-/- mice. Significantly, the kinase activity of Mnks 
seemed not to be essential for normal growth [30, 31]. As 
such, Mnks have emerged as potential effective and low 
toxicity targets for cancer therapy. 
We have previously described a novel CDK9 
inhibitor, CDKI-73, as a targeted therapeutic agent for 
the treatment CLL [32]. CDKI-73 is highly cytotoxic to 
primary leukemia cells derived from CLL patients (mean 
LD
50
 = 0.08 µM) and showed >500-fold selectivity for 
primary leukemia cells over normal B-lymphocytes (LD
50 
= 40.5 µM). Significantly, CDKI-73 retained efficacy 
in primary CLL samples derived from poor prognostic 
subsets including those who had p53 mutation/deletion 
and those who had relapsed following fludarabine-
based regimens. The synergistic effect of CDKI-73 with 
fludarabine was established at a molar ratio of 1:100, and 
the synergy mechanism was associated with CDKI-73- 
mediated transcriptional inhibition of Mcl-1, Bcl-2 and 
XIAP. The study has provided compelling evidence that 
CDKI-73 represents a promising therapeutic strategy as 
a single-target agent as well as combination therapeutics 
with fludarabine for the treatment of CLL and fludarabine-
relapsed diseases.
In the present study, we further evaluated the effects 
of CDKI-73 on human ovarian cancer cells. Ovarian 
cancer is the second most common gynecologic cancer; 
new and more effective treatments are urgently required. 
Screening against a panel of 24 human cancer cell lines 
showed that CDKI-73 was most cytotoxic against A2780 
ovarian cancer cells. We herein report that CDKI-73 
targets both CDK9- and eIF4E-related pathways and 
it may serve as an effective therapeutic agent for the 
treatment of ovarian cancer, as well as a range of other 
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Table 1: Effect of CDKI-73 on cell viability by 72 h MTT assay
Human cell line *IC
50
 (μmol/L) ± SD
Ovarian carcinoma A2780 0.007 ± 0.001
Epithelial carcinoma A431 0.057 ± 0.014
Colorectal carcinoma
COLO 205 0.071 ± 0.013
HCT-116 0.017 ± 0.007
Cervical carcinoma HeLa 0.031 ± 0.004
Prostate adenocarcinoma
LNCaP 0.057 ± 0.016
DU-145 0.042 ± 0.005
Breast adenocarcinoma
MCF-7 0.066 ± 0.011
MDA-MB-231 0.058 ± 0.004
T47D 0.071 ± 0.002
Pancreatic carcinoma PANC-1 0.573 ± 0.027
Leukaemia cell lineϯ
HL-60 0.033 ±  0.013
K562 0.517 ± 0.092
KG-1 0.045 ± 0.005
KYO-1 0.467 ± 0.011
Kasumi-1 0.038 ± 0.001
ME-1 0.363 ± 0.026
MOLM-13 0.033 ± 0.010
MV4-11 0.034 ± 0.005
NB4 0.054 ± 0.004
PL-21 0.037 ± 0.003
SET-2 0.477 ± 0.068
THP-1 0.062 ± 0.002
U937 0.012 ± 0.007
 *The data given are the mean ± SD derived from at least three replicates. 
 ϯ Determined using Resazurin assay.
Table 2: Effects of CDKI-73, Flavopiridol and CGP57380 on cell viability by MTT time-course experiments
IC
50
* (μmol/L) ± SD
Cell line Compound 24 h 48 h 72 h
A2780
CDKI-73 0.033 ± 0.002 0.010 ± 0.001 0.007 ± 0.001
Flavopiridol 0.049 ± 0.002 0.056 ± 0.010 0.036 ± 0.003
CGP57380 9.022 ± 1.068 7.427 ± 1.157 4.935 ± 0.229
A2780
(CDK9 shRNA)
CDKI-73 >10 0.985 ± 0.132 0.386 ± 0.036
Flavopiridol >10 0.245 ± 0.113 0.061 ± 0.014
*The data given are the mean ± SD derived from at least three replicates.
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cancers. 
RESULTS
CDKI-73 exhibits broad spectrum anti-cancer 
activity
CDKI-73, a heterocyclic 3-(5-fluoro-4-(4-methyl-
2-(methylamino)thiazol-5-yl)pyrimidin-2-ylamino)
benzenesulfonamide, was rationally designed and 
optimized using CDK9 protein structure-guided approach 
[33]. X-ray crystallographic analysis confirmed that 
CDKI-73 analogs targeted CDK9 in an ATP-dependent 
manner [34]. CDKI-73 is one of the most potent CDK9 
inhibitors identified to date [32, 33]. However, it also 
inhibits CDK1, CDK2 and CDK7 in the low nM range in 
biochemical kinase assays. 
We firstly assessed the effects of CDKI-73 on cell 
viability against a panel of 24 human solid tumor and 
hematological cancer cell lines using MTT and resazurin 
assays. The relevant half-maximal inhibitory concentration 
(IC
50
) values are summarized in Table 1. CDKI-73 has 
exhibited potent anti-proliferative activities against all 
tumor cell lines tested with IC
50
 values ranging from 0.007 
to 0.573 μM following a 72 h of exposure. CDKI-73 was 
most potent in A2780 ovarian cancer cells with an IC
50 
= 
0.007 μM. 
We next carried out time-course proliferation 
assays with CDKI-73 in A2780 cells compared with that 
of flavopiridol (Table 2). CDKI-73 inhibited the growth 
of tumor cells at early time-points, i.e. 24 h, with an IC
50
 
value of 0.033 µM; similar to flavopiridol (IC
50
 = 0.049 
µM). Prolonged exposure to CDKI-73 (i.e. 72 h) caused 
a significant reduced cell viability; showing a >5-fold 
higher potency than flavopiridol. CGP57380, a known 
Mnk inhibitor [28, 29], was included in the study as a 
comparator agent with targeted effects on the Mnk-eIF4E 
pathway. CGP57380 was significantly less active in 
inhibiting A2780 tumor growth (IC
50
 ≥5 µM) than CDKI-
73. 
CDK9 shRNA confirms the target specificity of 
CDKI-73 
To investigate the importance of CDK9 expression 
in A2780 cells and to assess the target specificity of CDKI-
73, we silenced CDK9 expression using a lentivirus-
mediated short hairpin RNA (shRNA) strategy [32]. A 
Figure 2: ShRNA-mediated CDK9 knockdown in A2780 cells. Lentivirus-containing CDK9 shRNA were used to transfect 
A2780 cells as previously described [32]. The level of CDK9 knockdown was quantified with three independent verifications by (A) Real 
Time-quantitative PCR (RT-qPCR) and (B) Western blot. (*) indicates p ≤ 0.05 compared to A2780 untransfected cells.
Figure 1: Chemical structure of CDKI-73
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stable knockdown of CDK9 was achieved to ~90% when 
compared to non-genetic modified A2780 cells in mRNA 
transcription (Figure 1A) and protein expression (Figure 
1B). These results confirmed the successful knockdown 
of CDK9 in A2780 cells. 
CDK9 knockdown (CDK9KD) A2780 cells have 
demonstrated significant resistance to CDKI-73. After 
treatment of CDK9KD cells with CDKI-73 for a period 
of 24 h, no cytotoxic effect was observed (IC
50
 >10 
µM). Following treatment for 48 h and 72 h, CDKI-73 
caused cell death, but revealed >98- and >50-fold reduced 
potency, respectively, compared to CDKI-73 in A2780 
parental cells (Table 2), confirming CDK9 targeting 
specificity of CDKI-73. CDK9KD A2780 cells also 
showed reduced sensitivity towards flavopiridol at 24 h 
treatment period, but the cells regained sensitivity by 48 
and 72 hours, suggesting off-target effects of flavopiridol 
[13]. 
CDKI-73 activates caspase-3/7 and induces 
apoptosis
To investigate whether apoptosis was the relevant 
mode of action observed in the viability assay, we 
measured the activity of caspase-3/7 in A2780 cells after 
exposure to CDKI-73 or flavopiridol for a period of 24 h. 
As shown in Figure 3A, 0.02 μM CDKI-73 significantly 
increased caspase-3/7 activity in A2780 cells and in a 
dose-dependent manner. Induction of the same level of 
Figure 3: Induction of apoptosis by CDKI-73 and CDK9 shRNA. (A) Caspase-3/7 activity in A2780 ovarian cancer cells 
following treatment with CDKI-73 or flavopiridol for 24 h. Dose-dependent activation of caspase-3/7 was observed in A2780 cells starting 
from 0.02 µM CDKI-73 and 0.06 µM flavopiridol. Vertical bars represent the mean ± SD of three independent experiments. Values 
significantly different from the untreated samples are marked with an asterisk (*) (p ≤ 0.05). (B) shRNA-mediated CDK9 knockdown and 
treatment with 0.25 µM CDKI-73 or flavopiridol induced apoptosis in A2780 cells following treatment for 48 h as analyzed by annexin-V/
PI assay. (C) Cell cycle analysis of A2780 cells after treatment with CDKI-73 or flavopiridol for 24 h. No detectable cell cycle effect was 
observed with CDKI-73- or flavopiridol-treated cells at 0.02 μM, the concentration causing a significant caspase-3/7 activation; at a higher 
concentration, i.e. 0.25 μM CDKI-73 or flavopiridol induced the significant numbers of sub-G1 cells, indicating cell death. The shRNA 
CDK9KD cells also showed no cell cycle disturbance.
Oncotarget7696www.impactjournals.com/oncotarget
caspase-3/7 requires 0.06 µM flavopiridol, consistent 
with its lower potency compared to CDKI-73 in the 
cytotoxicity assay. 
Induction of apoptosis in A2780 cells by either 
shRNA-mediated CDK9 knockdown or pharmacological 
inhibitors was further confirmed by annexin-V/propidium 
Figure 4: Mechanistic investigation of the molecular effects by Western blotting and RT-qPCR analysis. (A) A2780 cells 
were treated with CDKI-73, flavopiridol or CGP57380 for 1 h. CDKI-73 and flavopiridol reduced phosphorylation of RNAPII at serine-2 
at 0.06 and 0.25 µM, respectively, while CGP57380 only affected the phosphorylation of eIF4E (p-eIF4ES209) via inhibition of Mnk1. (B) 
After 24 h drug exposure, CDKI-73 or flavopiridol also abolished p-eIF4ES209 at 0.25 µM, indicating cellular inhibition of Mnk kinase 
activity. The same treatment with CDKI-73 or flavopiridol caused a loss in Mnk1 protein expression. CGP57380-treated cells abrogated 
p-RNAPIIS2 as well as p-eIF4ES209 with a minimal effect on Mnk1 protein level. (C) 0.25 µM CDKI-73 or flavopiridol caused little changes 
in the phosphorylation of Erk and p38 MAPK; however, inhibited the 4E-BP1 phosphorylation (p-4E-BP1Thr70) by 24 h. CGP57380 had a 
minimal effect on these proteins. (D) At 0.25 µM, CDKI-73 or flavopiridol suppressed the expression of anti-apoptotic proteins Mcl-1 and 
Bcl-2, leading to caspase-3/7 activation and PARP cleavage. In addition, MDM2 protein level was reduced and this was accompanied by 
the up-regulation of p53. CGP57380 reduced Mcl-1 and Bcl-2 proteins at a concentration of 20 µM, but caused little alterations in caspase-3 
activity and PARP cleavage, indicating a minimal apoptotic effect. DMSO diluent was used as a control in each experiment and β-actin was 
used as an internal loading control. A representative blot is selected from at least two independent repeats of experiments. The expression of 
mRNA encoding Bcl-2, Mcl-1 and Mnk1 were reduced by (E) CDKI-73 and (F) Flavopiridol in A2780 cells after treatment for 4 h starting 
at a concentration of 0.06 μM in a dose-dependent manner. (G) CGP57380 showed a minimal effect on these transcripts. Actin mRNA was 
used as a reference sequence. 
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iodide (PI) dual staining following treatment of cells for 
a period of 48 h (Figure 3B). ShRNA-mediated CDK9 
inhibition caused 59% apoptosis, as indicated by the 
annexin-V positive and PI negative (annexin-V+/PI-) 
cells. Similarly, treatment of A2780 cells with CDKI-73 
or flavopiridol at 0.25 µM resulted in > 48% increase 
in annexin-V+/PI- cells when compared to untreated 
cells. Taken together, these results confirmed that A2780 
cells are dependent on CDK9 activity for survival and 
inhibition of CDK9 activity by either genetic knockdown 
or pharmacological inhibitor promotes cellular apoptosis. 
As CDKI-73 was shown to inhibit CDK1 and 
CDK2 by in vitro kinase assays [32], we investigated the 
cell cycle effect of CDKI-73 on A2780 cells compared 
to that of CDK9KD cells. As shown in Figure 3C, no 
significant difference in the cell cycle profiles was 
observed in CDK9KD A2780 cells compared to the 
transfection controls (i.e. empty vector and scramble) 
and untransfected cells, confirming a lack of influence 
of CDK9 on cell cycle. Similarly, no cell cycle effect 
was observed with A2780 cells after exposure to 0.02 
µM CDKI-73 for 24 h, despite the fact that the same 
conditions have given rise to a significant caspase-3/7 
activity in the cells (Figure 3A). At a higher concentration, 
i.e. 0.25 µM, CDKI-73 induced substantial sub-G1 events, 
an indicative of cell death. Flavopiridol showed similar 
cell cycle profiles to CDKI-73. 
Figure 5: Mechanism of action of CDKI-73 in A2780 cells compared to shRNA-mediated CDK9KD in A2780 cells. (A) 
Western blotting analysis showed the reduced levels of CDK9 protein and p-RNAPIIS2 in CDK9 shRNA KD A2780 cells. Down-regulation 
of p-eIF4ES209 by shRNA-mediated CDK9KD indicated Mnk1 inhibition. Like CDK9 shRNA, CDKI-73 caused the loss of p-RNAPIIS2 and 
p-eIF4ES209 in A2780 cells. Unlike CDK9 shRNA, CDKI-73-treated cells showed a reduced p-RNAPIIS5, indicating CDK7 inhibition at 
0.25 µM. (B) Knockdown of CDK9 reduced the phosphorylation of Erk, p38 and 4E-BP1, suggesting a role of CDK9 in MAPK cascade and 
mTOR-eIF4E pathway. CDKI-73 had little effects on Erk and p38 MAPK and their phosphorylated forms. Like CDK9 shRNA, however, 
CDKI-73 inhibited the phosphorylation of 4E-BP1. (C) Knockdown of CDK9 suppressed Bcl-2, Mcl-1 (~ 40 kDa), procaspase-3/7 and 
PARP. CDKI-73-treated cells decreased Mcl-1, Bcl-2, procaspase-3/7 protein levels and induced cleaved PARP. DMSO diluent was used 
as a control in each experiment and β-actin was used as an internal loading control. A representative blot is selected from at least two 
independent repeats of experiments.
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CDKI-73 down-regulates the phosphorylation of 
RNAPII and eIF4E
We next investigated the effect of CDKI-73 on 
protein expression using Western blotting. A2780 cells 
were incubated with CDKI-73 for 1 h. The level of 
the phosphorylated RNAPII at serine-2 (p-RNAPIIS2, 
Figure 4A) was suppressed, starting from 0.06 μM in 
a dose-dependent manner. In contrast, the level of the 
phosphorylated serine-5 of CTD RNAPII (p-RNAPIIS5), 
and the proteins involved in the Mnk-eIF4E axis were not 
affected, indicating that CDK9 is the primary target for 
CDKI-73. Flavopiridol also reduced CDK9 activity, but 
this was only evident at a higher concentration (i.e. 0.25 
µM). CGP57380 demonstrated potent anti-Mnk activity 
by blockage of eIF4E phosphorylation at  serine-209 
(p-eIF4ES209) at 5µM. This compound had little effect on 
CDK9 and CDK7 kinase activity following 1 h-treatment. 
By extending the treatment to 24 h, both CDKI-73 
and flavopiridol abolished phosphorylation at serine-2 
and serine-5 of RNAPII at 0.25 µM, indicative of their 
cellular CDK9 and CDK7 inhibitory activities (Figure 
4B). Interestingly, both compounds were capable of 
blocking the Mnk-mediated eIF4E phosphorylation at 
the  serine-209 at the same concentration. Expectedly, 
CGP57380 inhibited the level of p-eIF4ES209 at 5 µM. 
However, it was surprising that CGP57380 also caused a 
loss in the phosphorylation of RNAPII (p-RNAPIIS2). No 
changes in the levels of total RNAPII and eIF4E proteins 
were detected in cells treated with compounds. However, 
the level of Mnk1 expression was reduced by 0.25 µM 
CDKI-73 or flavopiridol. These observations suggested 
that CDKI-73 (or flavopiridol) might also target the 
proteins involved in the eIF4E-mediated translation in 
cancer cells.
To assess whether CDKI-73 affected the MAPK 
and mTOR pathways, we examined their respective 
upstream protein expression and kinase activities. Mnk1 
kinase activity is known to be regulated by p38 MAPK 
and Erk through phosphorylation at Thr197 and Thr202, 
respectively [35]. p38 MAPK is activated by MKK3/6 
through phosphorylation at its Thr180 and Tyr182 
residues, wheras Erk is phosphorylated by MEK1 at 
Thr202 and Tyr204 residues. Western blotting analysis 
of A2780 cells following exposure to compounds for 24 
h revealed that, as shown in Figure 4C, neither CDKI-
73 nor flavopiridol had any effect on the Erk and p38 
MAPK pathways; no significant change in the levels of 
phosphorylated Erk (i.e. p-ErkT202/ T204), and p38 MAPK 
(i.e. p-p38T180/Y182) was detected, indicating their Mnk 
selectivity profile. However, the phosphorylation of eIF4E 
binding protein (4E-BP1) at Thr70, i.e. p-4E-BP1T70, was 
blocked by 0.25 µM CDKI-73 and flavopiridol (Figure 
4C). A reduction of 4E-BP1 protein was also observed. 
CGP57380 inhibited p38 phosphorylation, but showed a 
minimal effect on 4E-BP1. 
We further examined the changes of anti-apoptotic 
and onco-proteins including Mcl-1, Bcl-2 and cyclin 
D1, which are regulated by CDK9- and eIF4E-mediated 
transcription and translation, respectively [3, 29]. The 
expression of anti-apoptotic proteins Mcl-1 and Bcl-2 
was significantly reduced in A2780 cells after treatment 
with 0.25 μM CDKI-73 or flavopiridol, as well as 20 μM 
CGP57380 (Figure 4D). The treatment with CDKI-73 or 
flavopiridol also suppressed cyclin D1 protein expression. 
The loss in procaspase-3 and -7, together with the increase 
in cleaved PARP confirmed the induction of apoptosis 
by CDKI-73. Being consistent with previous studies 
of CDK9 inhibitors [13, 36], CDKI-73 increased p53 
protein expression concomitantly with down-regulation 
of MDM2, a short-lived protein responsible for p53 
degradation. Taken together, CDKI-73 demonstrated 
potent CDK9 inhibition as well as, the ability to block 
the eIF4E pathway by suppressing Mnk and 4E-BP1 
activities. This resulted in the reduction of Mcl-1 and 
Bcl-2 and promoted caspase-3/7-dependent apoptosis in 
A2780 cells. 
CDK9 inhibition causes the down-regulation of 
Mnk1 
To determine whether there is any inter-dependence 
between mRNA transcription and eIF4E translation, we 
examined the transcription of Mnk1, as well as Bcl-2 and 
Mcl-1 in A2780 cells. After 4 h treatment with CDKI-
73 (Figure 4E) or flavopiridol (Figure 4F), the mRNA 
levels of all three genes were reduced in a dose-dependent 
manner. In contrast, CGP57380 showed a minimal effect 
on these transcripts (Figure 4G), suggesting the CDK9-
mediated transcriptional inhibition of Mnk1, Mcl-1 and 
Bcl-2. The effects on CDK9 and Mnk-eIF4E pathways 
were further examined in the CDK9KD A2780 cells 
in comparison with CDKI-73-treated A2780 cells. As 
expected, down-regulation of CDK9 protein, its kinase 
activity (i.e. p-RNAPIIS2), and RNAPII was observed in 
the CDK9KD cells (Figure 5A). Significantly, shRNA-
mediated CDK9 inhibition also caused down-regulation 
of Mnk1 expression, resulting in a loss of eIF4E 
phosphorylation at  serine-209, consistent with the CDK9-
Mnk targeting mechanism of CDKI-73. Furthermore, 
the CDK9 knockdown caused loss in the levels of 
phosphorylated Erk, p38 and 4E-BP1 (Figure 5B). A 
slight reduction in p38 and 4E-BP1 protein expression 
was also observed. In contrast, other than the abrogated 
phosphorylation of 4E-BP1, CDKI-73 had little effect on 
the levels of other proteins examined. Ribosomal protein 
S6 (rpS6) and its phosphorylation (i.e. p-S6S240/S244) were 
not affected by either shRNA-mediated CDK9KD or 
CDKI-73. Induction of apoptosis by CDK9 shRNA was 
also associated with the loss of Mcl-1 and Bcl-2, the 
induction of caspase-3/7 activity and PARP cleavage. 
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DISCUSSION
Dysregulations of mRNA transcription and protein 
synthesis are common events in human cancers. CDK9 
and eIF4E are key regulators in mRNA transcriptional 
elongation and translational initiation, respectively. CDK9 
inhibition as an effective anti-cancer strategy has gained 
strong support in recognizing that cancer cells rely on the 
production of short-lived apoptosis regulators and mitotic 
regulatory kinases for survival [2, 3]. Our own studies have 
also demonstrated that CDK9 inhibitors can achieve anti-
cancer activity with minimal toxicity to non-transformed 
cells [13, 32]. Control of mRNA translation plays a critical 
role in cell growth, proliferation and differentiation. Most 
mRNAs are translated in a cap-dependent manner. A key 
player in the regulation of translation is the mRNA cap-
binding protein eIF4E, the rate-limiting member of the 
eIF4F complex. Overexpression of eIF4E has been found 
in a range of human cancers and phosphorylation of eIF4E 
by Mnks is responsible for the oncogenic role of eIF4E 
[28, 30]. Inhibition of Mnk-mediated eIF4E activity is 
believed to have a major impact on the PI3K/Akt/mTOR 
and Ras/Raf/MAPK pathways in human cancers [29, 37]. 
CDKI-73 is one of the most potent CDK9 inhibitors 
identified to date, and has been shown to induce apoptosis 
in CLL patient samples with minimal toxicity [32]. 
CGP57380 is a potent Mnk1 inhibitor (Ki = 0.34 µM) [38], 
and has served as a tool compound to reveal the role of 
eIF4E in cell biology [39]. CGP57380 also inhibits other 
kinases including CK1 (with a similar potency to Mnk1), 
BRSK2, MKK1 and Pim3 [40], however it dose not 
target CDKs. CGP57380 has been shown to block eIF4E 
phosphorylation in HCT-116 and B16 cell lines [41]. To 
determine whether targeting the Mnk-eIF4E axis in cancer 
cells is an additional mechanism to CDK9 inhibition or a 
consequence of CDK9 pathway alteration, we conducted 
experiments utilizing shRNA-mediated CDK9 inhibition 
to compare with the pharmacological effects of CDKI-73. 
Flavopiridol and CGP57380 were used as comparators 
for assessments of CDK9 and Mnk1 pharmacological 
mechanism, respectively. 
Despite the fact that CDKI-73 was highly cytotoxic 
to a wide range of tumor cell lines, particularly to A2780 
ovarian cancer cells (IC
50
 = 0.007 µM, Table 1), it had 
a reduced potency in the CDK9KD A2780 cells (IC
50
 = 
0.386 – < 10 µM, Table 2). These confirmed the CDK9-
targeting specificity of CDKI-73, as the down-regulation 
of anti-apoptotic proteins in the CDK9 knockdown 
cells reduced the sensitivity towards CDK9 inhibitor 
[42]. CDKI-73 induced significant caspase-3/7 activity 
at 0.02 µM (Figure 3A), and the concentration caused 
no cell cycle effect (Figure 2A and 2C), confirming its 
CDK9 inhibition mediated apoptosis. CDKI-73 induced 
substantial apoptotic populations; resulting in ~48% 
apoptotic cells as detected in annexin-V assay (Figure 
3B). Cell cycle analysis confirmed that CDKI-73 caused 
substantial cell death (i.e. sub-G1, Figure 3C). 
In line with our previous findings [32, 33], CDKI-
73 inhibits cellular CDK9-mediated RNAPII transcription. 
Western blotting of A2780 cells after exposure to 0.06 
µM CDKI-73 for 1 h reduced the phosphorylation CTD 
RNAPII at serine-2 (Figure 4A). In addition to targeting 
CDK9; and CDK7 to a lesser extent, CDKI-73 has shown 
to decrease the phosphorylation of eIF4E. As shown in 
Figure 5A, the combined suppression of p-RNAPIIS2 and 
p-eIF4ES209 were observed in the CDK9 shRNA KD cells, 
consistent with those shown in CDKI-73-treated cells 
and suggesting a role of CDK9 in the Mnk-eIF4E axis. 
The reduced mRNA transcript for Mnk1 as in Figure 5E 
further confirm that CDKI-73 inhibit Mnk-eIF4E axis 
through CDK9 transcriptional inhibition. Intriguingly, 
CGP57380 was shown to suppress the phosphorylation of 
RNAPII at serine-2. CGP57380 is known to target CK1 
with an IC
50
 = 0.51 μM in a biochemical assay [40]. It has 
been shown that CK1 activity is required for activation of 
heat shock proteins (Hsps) 70 and 90 [43], which in turn 
stabilize CDK9 binding to cyclin T1 leading to productive 
mRNA transcription [44]. Therefore, it is likely that the 
suppression of p-RNAPIIS2 by CGP57380 may through its 
off-target CK1-Hsp inhibitory mechanism. 
To further assess whether down-regulation of CDK9 
by shRNA affected Mnk up-steam activating kinases, 
we examined Erk and p38 MAPK phosphorylation in 
CDK9KD cells, both were abrogated. In contrast, CDKI-
73 (or flavopiridol) caused little changes in these proteins 
(Figures 4C and 5B). It is not understood why CDK9 
knockdown should cause the de-phosphorylation of 
Erk and p38; nevertheless suggesting a role of RNAPII 
in transcriptional regulation of Erk and p38 upstream 
modules. It is worth noting that the shRNA-mediated 
CDK9 inhibition silences the gene expression of CDK9 
and hence shutting off the protein synthesis in the cells, 
whereas pharmacological inhibitor CDKI-73 blocked only 
the kinase activity of CDK9 without affecting the protein 
expression. The difference has important implications; for 
instance, CDK9 knockdown causes alternation not only 
in a range of mRNA transcripts, but also in the proteins 
that interact with their binding partners or assemble into 
macromolecular complexes. 
Mcl-1 plays a pivotal role in maintaining 
mitochondrial outer membrane permeability. CDKI-
73 or CDK9 shRNA showed a significant apoptotic 
effect (Fig 4D and 5C). Reduction in procaspase-3 and 
procaspase-7 in CDKI-73-treated A2780 cells indicated 
the conversion of their respective procaspases to the active 
forms. This was further supported by the increased level 
of cleaved PARP. Mcl-1 and Bcl-2 were down-regulated 
following the CDK9 inhibition (Figure 4D, 4E and 5C). 
Expression of p53 is regulated at the post-translational 
level by association with its negative regulator MDM2 
[45], a short-lived protein known to be reduced by 
CDK9 inhibition [13]. As expected, CDKI-73 elevated 
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the level of p53 in concordance with a reduced MDM2. 
Flavopiridol showed similar effects on these proteins. 
Equally, shRNA-mediated CDK9KD resulted in reduction 
of procaspase-3, and in abrogation of procaspase-7, PARP 
and Bcl-2 proteins (Figure 5C). 
Interestingly, in concordance with the reduction of 
Mcl-1 protein (~40 kDa), a smaller species of Mcl-1 (~36 
kDa) was detected in the CDK9KD cells. Mcl-1 has been 
shown to have a triplet of 36-, 38-, and 40-kDa species, 
and the 36-kDa form is more stable compared to other two 
larger forms [46]. Structurally, Mcl-1 can be subdivided 
into the C-terminal region that shares homology with 
other anti-apoptotic family members, and the N-terminal 
region which is unstructured. The short half-life of Mcl-1 
is thought to reflect the unique features of its N-terminus. 
The latter contains two sequences rich in proline, glutamic 
acid, serine and threonine residues (so-called the PEST 
sequences) that target it for rapid proteasomal degradation 
[47, 48]. At least three E3 ubiquitin ligases are thought 
to contribute to this rapid turnover, and the ability of E3 
ligases to bind and modify Mcl-1 is dependent on the 
phosphorylation of Mcl-1 at certain sites within its PEST 
sequences. Active Erk has been shown to phosphorylate 
the PEST region which stabilizes Mcl-1. However, 
the phosphorylation by Erk can also serve as a priming 
phosphorylation for the subsequent glycogen synthase 
kinase-3 (GSK3)-mediated phosphorylation, which 
promotes Mcl-1 ubiquitylation and degradation [49]. 
Mnks play critical roles in the regulation of protein 
synthesis and have emerged as anti-cancer targets [28, 
29]. Recent studies have shown that the cytotoxic effects 
of Mnk inhibitors were cell-specific [50] and the anti-
proliferative effects of Mnk inhibitors in some solid tumor 
cells seemed primarily cytostatic, rather than cytotoxic 
[28]. Despite being a potent Mnk inhibitor, CGP57380 
exhibited only modest cytotoxicity in tumor cell lines 
[28]. We have shown that CGP57380 was capable of 
reducing the levels of Mcl-1 and Bcl-2 proteins (20 
µM, 24 h), but failed to activate caspase-3/7 and induce 
apoptosis in A2780 cells (Figure 4D). The observations are 
in agreement with the study of cycloheximide, a general 
translational inhibitor, which induced Mcl-1 protein decay 
by inhibiting the translational machinery without affecting 
cell apoptosis [51]. These suggest that down-regulation 
of Mcl-1 protein expression may be necessary, but not 
sufficient for induction of apoptosis, whereas CDK9-
targeted transcriptional inhibition of Mcl-1 should be more 
effective apoptotic strategy in cancer cells. 
Over the last decade, selectivity of kinase inhibitors 
has been the main focus of drug discovery in an attempt 
to reduce drug side-effects and toxicity. However, it 
becomes apparent from clinical studies with molecularly 
targeted therapy that cancers can escape from a given state 
of oncogene addiction through mutations in alternative 
pathways because of the frequent genomic instability of 
cancers. For this reason, as well as tumor heterogeneity, it 
is unlikely that the use of a single molecular targeted agent 
will achieve long-lasting remissions or cures in cancers, 
especially for late-stage disease [52]. Co-targeting key 
components of oncogenic pathways have recently been 
proposed as a more effective strategy for developing 
anti-cancer drugs [29]. With the combined inhibition of 
CDK9-mediated transcription and Mnk-eIF4E translation, 
together with its low toxicity in non-transformed cells and 
favourable pharmacological properties manifested [32], 
CDKI-73 may offer an opportunity to treat a wide range 
of human cancers. 
MATERIALS AND METHODS
Chemical compounds
Synthesis of CDKI-73 has previously been 
described [33]. Flavopiridol and CGP57380 were 
purchased from Sigma-Aldrich (Castle Hill, Australia). 
They were dissolved in dimethylsulfoxide (DMSO) at 
a stock concentration of 10 mM, and stored at -20°C in 
small aliquots.
Cell culture
A2780 cells were purchased from European 
Collection of Cell Culture (ECACC). All leukemia 
cell lines were kindly provided by Prof. R. D’Andrea 
(University of South Australia). All solid tumor cell 
lines were obtained from the cell bank at the Centre for 
Drug Discovery and Development, University of South 
Australia. All cell lines were maintained under 37oC, 
5% CO2, and were cultured in Roswell Park Memorial 
Institute (RPMI)-1640 with 10% FBS.
Lentiviral modulation of CDK9 in A2780 cells 
Transfection of cells with lentiviral particles 
containing CDK9 shRNA and verification of the 
percentage of knockdown were performed as previously 
reported [32]. Briefly, bacterial glycerol stocks containing 
the lentiviral plasmid vector pLKO.1-puro with shRNA 
inserts against CDK9, an empty vector or a scrambled 
shRNA control were obtained from Sigma Aldrich (Poole, 
UK). Lentivirus transfected 293T cells were incubated at 
37oC for 48h before the resulting lentiviral particles were 
harvested by centrifugation and concentrated using the 
Clontech Lenti-X concentrator kit (Lonza, Wokingham, 
UK). Concentrated virus was then added to A2780 cells 
and incubated for 48h. Lentivirus-transduced cells were 
then selected by addition of puromycin (1 μg/mL) to the 
culture for two weeks. The relative expression of CDK9 
was subsequently assessed by RT-qPCR and Western 
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blotting.
Cell viability assay
MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide) assays were performed 
in all solid tumor cell lines as reported previously [53]. 
Compound concentrations required to induce 50 % of 
cell viability (IC
50
) were calculated using non-linear 
regression analysis. Resazurin (Sigma Aldrich) assays 
were performed in all leukemia cell lines as previously 
described [38].
Caspase-3/7 assay
Activity of caspase-3/7 was measured using the 
Apo-ONE Homogeneous Caspase-3/7 kit (Promega, 
Madison, WI, USA) according to manufacturer instruction 
and analyzed using EnVision multi-label plate reader 
(PerkinElmer, Beaconsfield, UK).
Cell cycle and detection of apoptosis
A2780 (8 x 104) cells were seeded and incubated 
overnight at 37oC, 5% CO2. Followed by the treatment 
with compounds, cells were trypsinized and centrifuged 
(300 g, 5 min). Cell pellets were collected and fixed with 
70% ethanol on ice for 15 min, followed by centrifugation 
(300 g, 5 min). The collected pellets were incubated 
with staining solution (50 μg/mL propidium iodide (PI), 
0.1 mg/mL RNase A, 0.05% Triton X-100) at 37oC for 
1 h and analyzed with Gallios flow cytometer (Beckman 
Coulter, Brea, CA, USA). Apoptosis were assessed with 
cells collected and processed as described with annexin 
V-FITC/PI commercial kit (Becton Dickenson). Samples 
were analyzed with Gallios flow cytometer (Beckman 
Coulter, Brea, CA, USA) within 1 h of staining. Data were 
analyzed using Kaluza v1.2 (Beckman Coulter).
Western blots
Western blotting was performed either with the 
Simple Western assay by Simon (ProteinSimple, Santa 
Clara, CA, USA) according to manufacturer instruction 
[54] or as previously described [13]. Antibodies used were 
as follows: total RNAPII, phosphorylated RNAPII serine-2 
(p-RNAPIIS2) and serine-5 (p-RNAPIIS5) (Covance, NJ, 
USA), 4E-BP1, p-4E-BP1 (pT70), β-Actin, caspase-3, 
caspase-7, CDK9, eIF4E, p-eIF4E (S209), eIF4G, p-ErkT202/
Y204, p-p38T180/Y182, p38 MAPK, rpS6, Mcl-1, Mnk1, PARP, 
cleaved PARP (Cell Signalling Technology, Danvers, MA, 
USA), Erk (ProteinSimple), MDM-2 (Becton Dickenson, 
Franklin Lakes, NJ, USA), Bcl-2, cyclin D1, p-S6S240/
S244, p53 (Dako, Glostrap, Denmark). Both anti-mouse 
and anti-rabbit immunoglobulin G (IgG) horseradish 
peroxidase conjugated antibodies were obtained from 
Dako. Enhanced Chemiluminescence (ECL) reagents were 
obtained from GE Life Sciences.
Real Time-Quantitative PCR (RT-qPCR)
RNA extraction was performed using High Pure 
RNA Isolation Kit (Roche Applied Science, Castle 
Hill, Australia). 1 μg RNA was used in a 20 μl reverse 
transcription reaction using Transcriptor First Strand 
cDNA Synthesis Kit (Roche Applied Science, Castle 
Hill, Australia). RT-qPCR was carried out in duplicate 
with cDNA using SYBR Green I dye (Roche Applied 
Science, Castle Hill, Australia) and performed using 
LightCycler LC96 (Roche Applied Science, Penzberg, 
Germany). All primers were purchased from Sigma-
Aldrich (Castle Hill, Australia). Relative quantification 
using E-method established by Roche Applied Science 
was performed with β-Actin mRNA as reference 
sequence and untreated samples as study calibrator. 
cDNA samples were amplified using the following 
primer pairs with amplification efficiency (E): β-Actin: 
5’-ACTCTTCCAGCCTTCCTTC-3’ (forward) and 
5’-GATGTCCACGTCACACTTC-3’(reverse), E=1.72; 
Bcl-2: 
5’-ATGGGATCGTTGCCTTATGC-3’(forward) and 
5’-CAGTCTACTTCCTCTGTGATGTTGT-3’ 
(reverse), E=1.89; CDK9: 
5’-AAAACGAGAAGGAGGGGTTCC-3’ 
(forward) and 
5’-CCTTGCAGCGGTTATAGGGG-3’ (reverse), 
E=1.92; Mcl-1: 
5’-AACAAAGAGGCTGGGATGGG-3’ and 
5’-TGCCAAACCAGCTCCTACTC-3’ (reverse), E=1.80; 
Mnk1: 5’-AAGGCCATTGAGACACTTCG-3’ (forward) 
and 5’-CCCAAATGAAATAAAGCTCCTG-3’ (reverse), 
E = 1.74. 
Statistical analysis
All experiments with statistics were performed 
with at least two independent repeats; representative 
experiments being selected for figures. Statistical 
significance of differences for experiments was determined 
using one-way analysis of variance, with a minimal level 
of significance at p ≤0.05.
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